WO1997037999A1 - Composes synthetiques formant une triple helice - Google Patents

Composes synthetiques formant une triple helice Download PDF

Info

Publication number
WO1997037999A1
WO1997037999A1 PCT/US1996/004649 US9604649W WO9737999A1 WO 1997037999 A1 WO1997037999 A1 WO 1997037999A1 US 9604649 W US9604649 W US 9604649W WO 9737999 A1 WO9737999 A1 WO 9737999A1
Authority
WO
WIPO (PCT)
Prior art keywords
deoxy
ribofuranos
beta
group
dna
Prior art date
Application number
PCT/US1996/004649
Other languages
English (en)
Inventor
Barry I. Gold
Original Assignee
University Of Nebraska Board Of Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Nebraska Board Of Regents filed Critical University Of Nebraska Board Of Regents
Priority to AU55339/96A priority Critical patent/AU5533996A/en
Priority to PCT/US1996/004649 priority patent/WO1997037999A1/fr
Publication of WO1997037999A1 publication Critical patent/WO1997037999A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2

Definitions

  • the present invention relates to novel synthetic monomers that have the capacity to be assembled into defined oligomers which bind with sequence specificity to duplex Watson-Crick DNA via a triple helix motif. More particularly, the present invention discloses novel monomer molecules which, when assembled into defined oligomeric sequences, may be used for a variety of purposes related to target-specific control of gene expression.
  • each strand is a polynucleotide, i.e. a polymeric collection of four different types of nucleotide bases in which the sugar moiety of each nucleotide is linked by a phosphate group to the sugar moiety of an adjacent nucleotide.
  • each nucleotide contains a deoxyribose residue, a phosphate group and a purine or pyrimidine base.
  • Both the purine and the pyrimidine bases are flat, relatively water-insoluble molecules that tend to stack above each other at an angle shifted no more than about 25 degrees from perpendicular to the long axis of the double-stranded DNA helix, the shift being the result of natural tilt and propeller twist of the purine and pyrimidine bases.
  • the two complementary strands of the DNA double helix are joined by interstrand hydrogen bonding between complementary pairs of nucleotide bases.
  • An adenine (A) nucleotide base on one strand of the helix is always paired by hydrogen bonding with a thymine (T) nucleotide on the opposite strand, thereby forming an interstrand adenine—>thymine or thymine—>adenine base pair (A-T or T-A, respectively) .
  • a guanine (G) moiety on one strand is always paired with a cytosine (C) moiety on the opposite strand, thereby forming an interstrand guanine—>cytosine or cytosine—>guanine base pair (G-C or C-G, respectively) .
  • nucleotide sequence on one strand of the DNA double helix is the "sense” or “positive” strand sequence
  • nucleotide sequence on the opposite strand will be exactly complementary (according to the base pairing rules just cited) and is the "antisense” or “negative” strand sequence.
  • the sugar- phosphate backbones of the double helix are not equally spaced along the helical axis. This results in the formation of a "major” (wider) and a “minor” (narrower) helical groove in the B-DNA double helix.
  • B-DNA and closely related forms are the predominant class of DNA found in physiologic conditions. The availability of the wider spacing in the major groove in the duplex DNA molecule is of central - 3 - importance to the usefulness of the novel compounds of the present invention.
  • the hydrogen-bonding potential associated with the major groove shows much greater dependence on nucleotide base sequence than does the minor groove and, therefore, outside molecules (such as proteins or synthetic "antisense” oligomers) , which are influenced by nucleotide base sequence, form hydrogen bonds predominantly to specific groups positioned in the major groove.
  • Triple Helix Triple helix structures, first reported in 1957 from the combination of poly-adenylic acid (“poly-A”) with two equivalents of poly-uridylic acid (“poly-U”) (Felsenfeld et al., J. Amer. Chem. Soc. 79: 2023, 1957), have recently attracted a great deal of chemical and biological interest. It is known that the third pyrimidine strand, which resides in the major groove of duplex DNA, recognizes homopurine stretches and binds parallel to the purine strand (referred to as "parallel motif” or "pyrimidine motif” as shown in Figure 1) .
  • triplex triple helix
  • sugar puckers C3'-endo conformation
  • positive base pair tilt C3'-endo conformation
  • purines in the third strand
  • the recognition of the purine stretch in the duplex is anti-parallel (referred to as "purine motif” or "anti-parallel motif") .
  • Protonation is not required when the third strand uses the purine motif.
  • the third strand oligomer be charged. This is confirmed by observations that neutral oligomers such as the methylphosphonates do not form stable triplex structures with DNA.
  • the third strand oligomer (being an'Oligonucleotide") is usually synthesized to contain a phosphodiester backbone.
  • oligonucleotides with phosphodiester backbones have been limited in their utility as antisense molecules because of the significant nuclease susceptibility of the phosphodiester linkages.
  • the third strand binds asymmetrically in the major groove nearest to the sugar-phosphate backbone of the purine strand (FIGURE 1) .
  • any deviation from homopurine sequence requires that the traditional third strand actually cross over to the other side of the major groove (FIGURE 2) .
  • Limitations in the span and flexibility of the 5'-3'-linked deoxyribose/phosphodiester backbone do not allow this to occur.
  • any pyrimidine interruption in the homopurine strand cannot be accommodated by the traditional third strand and also significantly destabilizes traditional triple helix formation.
  • the major groove hydrogen-bonding information on the purine molec e targeted by the third strand is not the same for A-T as compared to T-A pairing (FIGURE 3) .
  • the open arrows containing the letter "A” indicate the hydrogen bond acceptor atoms
  • the open arrows containing the letter "D” indicate the hydrogen bond donor atoms.
  • the N7-adenine hydrogen bond acceptor and N 6 H 2 -adenine hydrogen bond donor are reversed for A-T relative to T-A pairing as viewed facing the major groove. This is equivalent to the thymine (T) of the third strand flipping as if the orientation of the strand changed from 3'-5' to 5 , -3'.
  • the synthetic oligo eric molecules of the present invention permit any known duplex DNA and/or RNA sequences to be targeted, including the usual duplex DNA and/or RNA sequences which contain heterogeneous (mixed) sequences of purines and pyrimidines.
  • Synthetic oligomers containing these novel bases recognize major- groove hydrogen bonding information associated with the purine and, optionally, the pyrimidine bases contained in each interstrand nucleotide base-pair combination in the targeted gene sequence.
  • the orientation of the backbone of these oligomers enables them to fit the major groove of a mixed purine-pyrimidine duplex.
  • oligomers comprising the synthetic monomeric compound of this invention form stable sequence-specific triple helix structures with duplex (double-stranded) Watson-Crick DNA molecules, and do so in such a way that the sugar-phosphate backbone of the synthetic oligomer lies near the center of the major groove of the duplex DNA structure.
  • these novel oligomers recognize nucleotide base sequences in double- stranded DNA without the limitation that the binding be done at low pH, or that the targeted sequence be only a homogeneous sequence of either purines or pyrimidines, the construction of triple helix-forming oligomers directed against any known heterogeneous sequence of purines and pyrimidines (as is commonly found in viral or non-viral sequences) is straightforward.
  • novel triple helix-forming oligomers wherein the nucleotide monomeric units are comprised of certain carefully designed quinoline and quinazoline residues (comprising a quinoline or quinazoline base moiety, an attached sugar component, and an attached phosphate component) .
  • These novel residue units can be grouped according to which of the interstrand G-C, C-G, A-T or T-A nucleotide base pairings in a targeted duplex DNA molecule the compounds bind.
  • the specificity of binding by the novel monomers is dictated by the spatial arrangement of hydrogen-bond acceptor and hydrogen-bond donor sites of the interstrand G-C, C-G, A-T or T-A nucleotide base pairs.
  • a substituted quinoline is provided which has the following formula:
  • X is selected from the group of H,C0 2 " , CS 2 ' and S0 3 " ;
  • Y is selected from the group consisting of NRR', OR, SRR', SR, PRR' and NHCOR;
  • R and R' are the same or different and are selected from the group consisting of hydrogen, lower alkyl, carboxyl and C 6 -C, 2 hydrocarbon aryl;
  • Z is C or N; and
  • W is a substituent that enables linkage of the quinazoline to another quinazoline or quinoline of the invention, preferably via a sugar- phosphate backbone, and is most preferably selected from the group consisting of a halo, a 2 '-deoxy-beta-D- ribofuranos-1-yl; and a 5'-monophosphorylated-2*-deoxy- beta-D-ribofuranos-1-y1.
  • the monomeric quinoline- or quinazoline-based compounds of the present invention are herein referred to as "anti-GC", “anti-CG”, “anti-AT” and “anti-TA”, based on which of the interstrand nucleotide base pairs in duplex Watson-Crick DNA molecules each specifically recognizes for binding.
  • exemplary of the novel monomers of this invention are the co ⁇ unds represented by the formulas set forth in FIGURE 4 which are denominated "anti-AT”, “anti-TA”, “anti-GC” and “anti-CG”.
  • anti-AT and anti-TA the following substituients are preferred.
  • X is -NH 2 , -OH, -SH, -PH 2 or -NHCOR; Y is -H, -NH 2 , -OH, -SH, -PH 2 or -NHCOR; R is -H, -alkyl or -aryl; and W is halogen or deoxyribose.
  • the exemplary quinoline compounds of Figure 4, anti-GC and anti-CG, comprise the following preferable substituents: X is -H, -C0 2 " , -CS 2 " , or -S0 3 " ;
  • Y is -NH 2 , -OH, -SH, -PH 2 , or -NHCOR;
  • Z is -CH, or -N;
  • R is -H, alkyl, aryl, or nothing (when Z is -N) ; and W is halogen or deoxyribose.
  • the "anti-bases" of this invention are herein referred to as TRIPSIDEs for the deoxyribose-substituted compounds, or TRIPTIDEs for deoxyribosephosphate compounds.
  • the halogenated precursors are referred to as TRIPs.
  • OLIGOTRIP is used to refer to an oligomeric TRIPTIDE that is designed to be the third strand in a triple helix motif, and wherein the TRIPTIDE units are generally linked through a sugar phosphate backbone, as described more fully hereinafter. This nomenclature is discussed more fully hereinafter.
  • substitutions on the quinazoline or quinoline ring structures are designated by R, W, X and Y in FIGURE 4.
  • W is a halogen group
  • the halogen of choice is chlorine, bromine or iodine.
  • alkyls generally having between about 1-10 carbons.
  • Lower-alkyls are preferred; for example, methyl, ethyl, n-butyl, n-propyl, and their branched chain derivatives.
  • R can also be an aryl, generally having between about 6-12 carbons and which can be substituted or unsubstituted. It is preferred that, when substituted, the substitutions be lower alkyls.
  • R and its substituted derivatives are those that they must not interfere either in the capacity of the substituted TRIP to be linked into an oligo eric structure (an OLIGOTRIP) , or in the capacity of the OLIGOTRIP to bind in the major groove of the targeted duplex DNA.
  • Use of molecular modeling techniques in most cases will reveal whether a selected substituent will be effective or not.
  • the substituents represented by X and Y in FIGURE 4 are -NH 2 -OH, -SH or -PH 2 groups. (These groups can also be further substituted as described hereinafter.) These substituents appear to best satisfy the critical requirement that such substituents provide effective and appropriate hydrogen bond donor or acceptor atoms at precisely the correct position to optimize binding of the substituted monomeric compound to the appropriate and complementary nucleotide base pair in the targeted DNA double helix.
  • the concept of acceptor and donor atoms in the formation of hydrogen bonds is shown in FIGURE 3, where the open arrows containing the letter "A" indicate the hydrogen bond acceptor atoms, and the open arrows containing the letter "D” indicate the hydrogen bond donor atoms.
  • the TRIPs of the this invention are useful as intermediates for the synthesis of the TRIPSIDES of this invention.
  • the latter are depicted in FIGURE 4 when W is a deoxyribose moiety (e.g., a 2'-deoxy-beta-D- ribofuranos-1-yl) .
  • W is a deoxyribose moiety
  • These TRIPSIDES are precursors for synthesizing the novel oligomeric OLIGOTRIPs of the present invention and constitute the repeating units of such OLIGOTRIPs when appropriately linked through suitable sugar backbones as discussed more fully hereinafter.
  • the quinazoline compositions of this invention are "anti-AT” or “anti-TA”, and the quinoline compositions are “anti-GC” or “anti-CG”.
  • TRIPs When these compounds are halogenated at the 4-position or the 5- position, they are herein referred to as TRIPs.
  • a linking substituent such as ribose, deoxyribose or amino acid units (e.g., N-(2- a inoethyl)glycine) , the compounds are herein referred to as TRIPSIDEs, consistent with standard nucleotide nomenclature.
  • TRIPTIDEs The phosphorylated derivatives of the present invention are herein referred to as TRIPTIDEs.
  • TRIPTIDE is herein used when reference is made in the following discussion to the substituted quinoline- or quinazoline-bases when they are already part of an oligomeric structure.
  • OLIGOTRIP is used herein to refer to a polymer comprising TRIPTIDE repeating units. According to the present invention, an OLIGOTRIP is designed to be the third strand in a triple helix motif. All other standard nucleotide nomenclature is believed to have been maintained.
  • the unique oligomers of this invention have clear advantages over traditional triple helix motifs.
  • One significant advantage is that heterogeneous (mixed) sequences of purines and pyrimidines in the duplex DNA molecules can now be targeted in forming a triple helix structure; the traditionally-limiting requirement of targeting only homopurine/homopyri idine nucleotide sequences is now eliminated.
  • Another clear advantage of the OLIGOTRIPs of the present invention is that protonation of cytosine (C) , which is essential in forming stable traditional C + -G-C triplex complexes using the pyrimidine motif, is no longer required.
  • the OLIGOTRIPs herein described are designed to effectively utilize the major-groove hydrogen-bonding information associated with purine and, optionally, pyrimidine bases in the targeted DNA molecule. This feature eliminates the constraint of homopurine stretches heretofore required for formation of triple helix motifs. As a result, the OLIGOTRIPs of this invention form very stable sequence-specific triple helix structures which lie with their sugar-phosphate backbone near the center of the major groove of the targeted double-stranded DNA molecule.
  • Anti-AT TRIPS and Anti-AT TRIPSIDEs are substituted monomeric quinazoline-based compounds which are capable, when incorporated into an oligomer of such monomers, of complementary binding to an adenine— >thymine (A-T) interstrand base pair in a DNA double helix.
  • A-T adenine— >thymine
  • the formula in FIGURE 4, designated "anti-AT”, is exemplary of such "anti-AT” TRIP compounds, when W is a halogen group. It is exemplary of an "anti-AT” TRIPSIDE when W is a deoxyribose sugar group.
  • Anti-GC TRIPs and Anti-GC TRIPSIDEs Falling within this group are substituted monomeric quinoline- based compounds which are capable, when incorporated into an oligomer of such monomers, of specific binding to a guanine—>cytosine (G-C) interstrand base pair in a DNA double helix.
  • the formula in FIGURE 4 which is designated "anti-GC” is exemplary of an “anti-GC” TRIP compound when W is a halogen group. It is exemplary of an "anti-GC” TRIPSIDE when W is a deoxyribose sugar group.
  • Anti-TA TRIPs and Anti-TA TRIPSIDEs Substituted monomeric quinazoline-based compounds which are capable, when incorporated into an oligomer of such monomers, of specific binding to a thymine—>adenine (T- A) interstrand base pair in a DNA double helix fall in this group.
  • the formula in FIGURE 4 which is designated "anti-TA” is exemplary of an "anti-TA” TRIP compound when W is a halogen group. It is exemplary of an "anti-TA” TRIPSIDE when W is a deoxyribose sugar group.
  • Anti-CG TRIPS and Anti-CG TRIPSIDEs This group includes substituted monomeric quinoline-based compounds which are capable, when incorporated into an oligomer of such monomers, of specific binding to a cytosine—>guanine (C-G) interstrand base pair in a DNA double helix.
  • the formula in FIGURE 4 which is designated "anti-CG” is exemplary of an "anti-CG” TRIP compound when W is a halogen group. It is exemplary of an "anti-CG” TRIPSIDE when W is a deoxyribose sugar group.
  • each monomeric TRIP compound of this invention when converted to its corresponding TRIPTIDE and incorporated via synthetic pathways described more fully hereinafter, into a polymeric OLIGOTRIP molecule, is designed to bind specifically to only one type of interstrand nucleotide base pair in a double-stranded DNA helix.
  • the synthetic oligomeric OLIGOTRIPs of the present invention have the capacity to associate by hydrogen bonding with sequence specificity, via a stable triple helix motif, to targeted nucleotide sequences in duplex Watson-Crick DNA.
  • each TRIP monomer (and its corresponding TRIPSIDE and TRIPTIDE monomers) associates by hydrogen bonding to the purine partner or to both the purine and the pyrimidine molecules in an interstrand base pair in a targeted double-stranded DNA helix, both strands of the targeted duplex DNA molecule can thereby be involved in the binding strategy.
  • Illustrative of this concept is the following diagram, which shows a sequence of certain novel quinoline- and quinazoline-based compositions, each in the form of a preferred embodiment of the present invention and linked together by a sugar-phosphate backbone, running in the 3'-to-5' direction, with the targeted DNA strand on the viewer's left running in the 5'-to-3' direction, from top to bottom): target DNA "ANTISENSE” duplex OLIGOTRIP
  • anti-AT is: 2-amino-4-(2'-deoxy-beta-D- ribofuranos-1-yl)-7- hydroxyquinazoline;
  • anti-TA is: 2-amino-5-(2'-deoxy-beta-D- ribofuranos-1-yl) -7- hydrozyquinazoline;
  • anti-GC is: 2-amino-4 (2 '-deoxy-beta-D- ribofuranos-1-yl) -7- carboxyquinoline;
  • anti-CG is: 2-amino-5-(2'deoxy-beta-D- ribofuranos-1-yl) -7- carboxyquinoline.
  • the "-yl” term refers to the position of sugar attachment to the TRIP moiety, and the TRIPTIDEs are connected by a conventional phosphate linkage.
  • novel compounds of the present invention are designed to bind near the center of the major groove by recognizing major groove hydrogen bor ing information and by virtue of a unique backbone conf ..mation, thereby eliminating the severe limitations of tr 2 traditional homopurine and homopyrimidine triple helix motif.
  • FIGURE 5 The structure of certain preferred embodiments of the novel quinoline- and quinazoline-based compositions of the present invention are shown in FIGURE 5.
  • W is a halogen group
  • the structures in the FIGURE represent an especially preferred embodiment of the TRIP bases of the present invention.
  • W is a deoxyribose sugar moiety
  • the structures in this FIGURE represent an especially preferred embodiment of the TRIPSIDEs of the present invention.
  • Also shown in this FIGURE is the relative spacial positioning of each novel base an its targeted interstrand nucleotide pair.
  • FIGURE 1 shows traditional triple helix (Dervan picture) and Hoogsteen base pairing for C * —G-C and —A-T (reproduced from Strobel et al., J. Amer. Chem. Soc. 110: 7927, 1988).
  • the double-stranded sequence is Sequence I.D. No.l; the triple helix-forming strand is Sequence I.D. No. 2.
  • FIGURE 2 diagrams how a purine-pyrimidine sequence requires part of the backbone of the third helical strand in the major groove to flip for A-T recognition on the two grooves (reproduced from Home & Dervan, J. Amer. Chem Soc. 112: 2435, 1990)
  • the double- stranded sequence is Sequence I.D. No. 3; the triple helix-forming strand is Sequence I.D. No. 4.
  • FIGURE 3 shows the hydrogen bond donor and acceptor sites for G-C and A-U (equivalent to A-T) pairings as are available in the major groove of a duplex DNA molecule (modified from W. Saenger: Principles of Nucleic Acid Structure, Springer-Verlag, New York, 1984, p. 123) .
  • FIGURE 4 shows where chemical substitutions may be made in the monomeric quinoline- and quinazoline-based compositions of the present invention.
  • FIGURE 5 shows the structure of certain preferred embodiments of the novel quinoline- and quinazoline-based compositions of the present invention.
  • Fig. 5A shows compositions designed to recognize all H- bond information in the major groove (purine and pyrimidine combined) .
  • Fig. 5B shows compositions of the invention that recognize only purine H-bond information in the major groove.
  • Fig. 5C shows compositions of the invention and compares compositions recognizing only purine H-bond information in the major groove ("motif A") with compositions recognizing all major groove H-bonding information (“motif B”) .
  • FIGURE 6, 7, 8 and 9 show computer-simulated three dimensional molecular modeling images of the precise spatial relationship of each of the different quinoline- and quinazoline-derived bases to the interstrand nucleotide pair to which it specifically binds in a targeted duplex DNA molecule.
  • FIGURE 6 shows the precise spatial arrangement of anti-GC with targeted interstrand G-C nucleotide base pair in duplex DNA.
  • FIGURE 7 shows the precise spatial arrangement of anti-AT with targeted interstrand A-T nucleotide base pair in duplex DNA.
  • FIGURE 9 shows the precise spatial arrangement of anti-TA with targeted interstrand T-A nucleotide base pair in duplex DNA.
  • FIGURES 10, 11, 12, and 13 demonstrate the pathways for synthesizing certain of the novel TRIPS of the present invention; shown are 4-chloro-anti-GC (FIGURE 10); 5-chloro-anti-CG (FIGURE 11); 4-chloro-anti-AT (FIGURE 12); and 5-chloro-anti-TA (FIGURE 13).
  • FIGURE 14 shows the synthesis of the deoxyribose sugar-containing TRIPSIDEs from the TRIP bases.
  • FIGURE 15 diagramatically illustrates alternative pathways for synthesizing novel TRIPs of the present invention, which are 4-bromo-anti-GC; 5-bromo- anti-CG; 4-bromo-anti-AT; 5-bromo-anti-TA.
  • FIGURE 16 shows the synthesis of a deoxyribose synthon, which is coupled with TRIP bases to form TRIPSIDEs of the invention.
  • FIGURE 17 shows an alternative synthesis of an anti-TA TRIPSIDE of the invention.
  • the TRIP bases of the present invention may be synthesized in two general motifs.
  • the bases are designed to recognize H-bond information contributed by purines in the major groove of duplex DNA. This motif is sometimes referred to herein as "motif A.”
  • the bases are designed to recognize both purine- and pyrimidine-contributed H-bond information in the major groove. This embodiment is sometimes referred to herein as "motif B.”
  • the general description set forth in the paragraphs below apply to either motif A or motif B.
  • TRIPS of the present invention are exemplified by compounds connected via a sugar-phosphate backbone
  • backbone structures known in the art (e.g., 5'-2' sugar phosphate linkages, peptide linkages) also may be used to produce the novel OLIGOTRIPS of the present invention.
  • the synthetic bases are planar aromatic bases. To ensure energetically favorable pi-stacking interactions required for stable helix formation, and to generate near "natural" helical twist angles, it is necessary that any synthetic base being newly designed for use in a synthetic oligomer be a planar aromatic system with at least one heteroatom.
  • heteroatom as used in this context and hereinafter means an atom other than carbon. The significance of good stacking interactions cannot be underestimated in designing third strand bases (Manzini et al., J. Mol. Biol. 213: 833, 1990).
  • the quinoline and quinazoline TRIPs of the present invention meet this criterion.
  • the synthetic bases recognize hydrogen bonding information in the major groove.
  • the hydrogen bond donor and acceptor atoms located in the major groove are: N7-purine (acceptor) , 0 4 -thymine (acceptor) , N 4 H 2 - cytosine (donor) , N 6 H 2 -adenine (donor) and 0 6 -guanine (acceptor) (FIGURE 3) .
  • the geometrical center of the hydrogen bonding information is associated with the 6-position of the purine, although it is important to emphasize that this is not the center of the major groove.
  • the distance from N7-purine to the exocyclic 4-position (oxygen or nitrogen) of the paired pyrimidine in Watson-Crick DNA is approximately six Angstroms in the B-form of DNA (B-DNA; see below) based on Dreiding molecular models and X-ray derived structures.
  • B-DNA B-form of DNA
  • FIGURES 4 and 5 are representative only, and are not precisely aligned (correct computer-generated spatial alignments are shown in FIGURES 6, 7, 8 and 9).
  • the distance across the groove between the glycosidyl N's on the purine and pyrimidine is approximately 9.7 Angstroms. Obviously groove dimensions are dependent on many factors related to sequence and the associated DNA conformations.
  • the synthetic bases differentiate between interstrand G-C and C-G bonding.
  • FIG. 3 and with an interstrand C-G (donor-acceptor- acceptor) base pairing differ; the third strand must be able to differentiate between these two pairing arrangements to afford high sequence specificity and to allow for reliable recognition of heteropurine/pyrimidine tracks.
  • the optimum angle for the three atoms is between 150-177°, although smaller angles have been reported (Jeffrey & Takagi, Ace. Chem. Res. .1JL: 264, 1978) .
  • substituted quinoline-based compounds "anti-GC” (2-amino-7-carboxyquinolin-4-yl) and “anti-CG” (2-amino-7-carboxyquinolin-5-yl) of the present invention have pKa's that indicate that the carboxyl and the quinoline ring nitrogen are both ionized at neutral pH and form three hydrogen bonds with the proper orientation for bonding with interstrand G-C and C-G nucleotide base pairs in targeted DNA molecules.
  • Anti-CG or anti-GC do not bind to interstrand A-T or T-A base pairs because the angular C-H of the quinoline ring system sterically blocks association with A-T or T-A pairings; the donor- acceptor arrangement also does not coincide with the hydrogen bonding atoms of the A-T or T-A pairings.
  • the angular C-H does not sterically interact with the 0 6 - guanine position.
  • the donor N 4 -cytosine, and receptors 0 6 -guanine and N7-guanine make the necessary hydrogen bonds with the carboxylate anion, the protonated ring nitrogen and the exocyclic amino group.
  • the pKa of the ring nitrogen of 2- aminoquinoline is 7.3 and the 7-carboxy group has only a minor effect on the pKa. Therefore, the requirement for low pH to effect triple helical formation, as is required for the association of C * — G-C in a traditional triplex structure, is not necessary with the novel OLIGOTRIPs of this invention.
  • the angular C4-H (anti-CG) or C5-H (anti-GC) prevents rotations of the quinoline ring around the glycosidyl bond and fixes the TRIP in the anti- configuration with respect to the deoxyribose ring.
  • the sugar connection to either the C-4 or C-5 position furnishes a carbon bond to the sugar that is perpendicular to the hydrogen bonding atoms of the monomeric TRIP and, therefore, provides the centrally located backbone that is necessary to accommodate mixed purine-pyrimidine runs.
  • the synthetic bases differentiate between interstrand T-A and A-T base pairings.
  • interstrand A-T and T-A base pairings at the simplest level are equivalent in terms of hydrogen bonding information.
  • FIGURES 4 and 5 This difference is depicted in FIGURES 4 and 5, which underscores two key points: 1) the steric interaction between the angular C8-H of the quinazoline ring system and the exocyclic NH 2 group of adenine; and 2) the requirement that the three atoms in a hydrogen bond interaction (X-H Y) form an angle of 160-178°.
  • the novel anti-TA moiety of the present invention can form three hydrogen bonds only to an interstrand T-A base pair because the C8-H can only accommodate the correct base pair match. In fact, it does not form more than one reasonable hydrogen bond to the interstrand A-T pair.
  • the novel anti-AT moiety of the present invention specifically interacts with interstrand A-T only and not with T-A pairing. Neither of these compound have any steric interaction with the 5-methyl group of thymine.
  • the quinazoline ring system is especially useful in the present invention because of its angular C8-H which causes powerful steric interferences with the "wrong" duplex base pairs, and because the pKa of 2- a inoquinazoline is approximately 4.8; this means that the ring N-l is not protonated.
  • 2- aminoquinoline has a pKa of approximately 4.9 for quinoline itself.
  • the 7-hydroxyl substitution on the quinazoline ring system increases the pKa by 0.5 unit, as indicated by the 5.5 pKa of 7-hydroxyquinoline.
  • Exemplary synthetic bases are produced from syntheses compatible with phosphoramidite chemistry.
  • the wide use of solid support-based DNA synthesis employing mechanized phosphoramidite chemistry makes this method of oligomer production most attractive.
  • the sugar-phosphate backbone structure of the oligomeric OLIGOTRIPs of the present invention is readily synthesized as either a phosphodiester or a phosphorothioate backbone.
  • the backbone of the third strand has to traverse a distance across the major groove that is almost six Angstroms more than is required in a homogeneous stretch of purines. This abrupt shift across the major groove is not possible with triplex strands containing the usual 5'-to-3' sugar-phosphate backbone.
  • the breakthrough tactic of the present invention eliminates the need for these molecular gymnastics.
  • the center of hydrogen bonding information is placed at a position six Angstroms from the glycosyl nitrogen of the purine nucleotides in the base sequences being targeted in the major groove of the double-stranded DNA molecule. Therefore, in a targeted heterogeneous sequence of purines and pyrimidines, the third strand has to traverse only an additional 1.5 Angstroms across the major groove to accommodate the optimal bonding distances between purine and pyrimidine bases in the targeted sequence.
  • Another backbone structure that can be utilized in the present invention is an amino acid linkage, such as N-(2-aminoethyl)glycine, to join the TRIP bases.
  • This linkage has been used to produce DNA analogs (termed “PNA” that exhibit hybridization characteristics obeying Watson-Crick hydrogen bonding rules (Egholm et al., Nature 365: 566-568, 1993).
  • DNA is conformationally promiscuous and is "free” to adopt a multitude of structures depending on the free energy of the system (duplex DNA of A-DNA or B-DNA structures, third strand, ligands, salts, water, etc) .
  • Oligodeoxyribonucleotides Antisense Inhibitors of Gene Expression, (J.S. Cohen, Ed.) CRC Press, Boca Raton, FL, 1989) .
  • Antisense oligonucleotides are traditionally single-stranded nucleic acids which, by hybridizing either to the complementary DNA nucleotide sequence in a target gene, or more commonly, to the messenger RNA (mRNA) transcribed from that gene, are able to reduce or abrogate the function of the targeted gene.
  • synthetic strings of the novel monomeric compositions of the present invention are designed to be complementary and to bind with a specific information- bearing sequence of paired nucleotide bases in a targeted double-stranded DNA helix. Because these sequence- specific, complementary OLIGOTRIPs target duplex (double- stranded) DNA rather than cell and tissue proteins, they have the potential to be drugs that are an order or so of magnitude more selective than traditional drugs, a factor which should very significantly reduce problems of unwanted side effects.
  • the current thinking in antisense oligonucleotide therapy is to utilize homologous DNA- based oligonucleotides as therapeutic agents; i.e., as agents whose nucleotide base sequence is complementary to all or part of the nucleotide sequence of a cellular or viral gene believed to be important in causing or regulating a disease process.
  • synthetic agents i.e., as agents whose nucleotide base sequence is complementary to all or part of the nucleotide sequence of a cellular or viral gene believed to be important in causing or regulating a disease process.
  • OLIGOTRIPs utilizing the novel monomeric compositions of the present invention, can be targeted to selected gene sequences for the purpose of controlling the expression of the targeted gene and formation of its product.
  • the size of the synthetic oligomer i.e., the number of bases in the OLIGOTRIP sequence, is an important consideration.
  • the length (in base numbers) of a traditional therapeutic antisense oligonucleotide ranges from at least about 8 bases to as many as about 100 bases.
  • the region of the target DNA to which the selected OLIGOTRIP is designed to hybridize is an important variable that affects the practice of this invention.
  • Several criteria are used herein to select the targeted region. These are: (i) thermal stability of the hybrid complex; (ii) secondary structure in the targeted DNA region; and (iii) the transcriptional activity of the targeted region (i.e., the targeted region must be transcriptionally active so that physical accessibility is guaranteed) .
  • the OLIGOTRIPs of the present invention are also useful as research tools, i.e., for experimental modification of a target DNA sequence of interest.
  • OLIGOTRIPs may be used for targeted delivery of DNA alkylating agents for studying the effect of such agents on gene expression.
  • the impetus for designing targeted equilibrium binding DNA alkylating agents arises from the knowledge that, although the modification of DNA is the initial step in the mechanism of action for many mutagens, carcinogens and antineoplastic agents, there is currently no common theme to the structure of the adducts or the sites of DNA modification.
  • the powerful liver carcinogen, aflatoxin B appears to selectively form an adduct at 7-G, and this DNA modification is thought to be responsible for its tumorigenicity.
  • the same 7-G site is considered to be relatively unimportant in the induction of hepatic tumors by methylating and ethylating agents that react at a variety of positions on the DNA in addition to 7-G.
  • the diversity and variation in product yields makes it difficult to dissect the importance and roles of individual DNA lesions in mutagenicity and/or cytotoxicity.
  • OLIGOTRIPs of the present invention are capable of modification to incorporate various alkylating agents, and therefore should be of particular utility in target- specific delivery of these agents to a DNA sequence under investigation. A preferred method for appending an alkylating functionality on to an OLIGOTRIP is described in detail in Example 9.
  • the gene that encodes the cancer-related p53 protein is a gene target of particular interest to research and clinical oncologists, as it is considered to occur more frequently among human cancers than does any other cancer-related gene yet identified. Accordingly, p53 is a preferred target of the novel compositions of this invention.
  • a number of cancers known to carry this gene are, for example, leukemias, lymphomas, myeloma, breast cancer, gastro-intestinal cancers, and small cell carcinoma of the lung.
  • the method of the present invention for killing or inhibiting the growth of cancer cells involves contacting cancer cells in vivo or in vitro with a cytotoxically-effective amount of an appropriate OLIGOTRIP or combination of OLIGOTRIPs, or pharmaceutically-effective analogs thereof.
  • the OLIGOTRIP or combination of OLIGOTRIPs, or pharmaceutically-effective analogs thereof have TRIP-based sequences complementary to a sequence of interstrand nucleotide base pairs in the DNA of the p53 gene present in the cancer cells.
  • cytotoxically-effective amount means an administered amount of a therapeutic OLIGOTRIP preparation which is well below the cytotoxic endpoint of the OLIGOTRIP preparation, but which is sufficient to kill or inhibit the growth of target tumor cells containing the targeted gene, in preference to other cells which do not contain the targeted gene.
  • a targeted cancer- related gene is the gene encoding p53.
  • the present invention also provides novel methods for treating an individual whose cancer cells contain a certain gene (or genes) which are identified as being related to the process of tumor development.
  • a certain gene or genes which are identified as being related to the process of tumor development.
  • exemplary of such a gene is the gene encoding the cancer- related p53 protein.
  • the methods for treating an individual with cancer involves the use of antisense
  • OLIGOTRIP therapies in which a cytotoxically-effective amount of a preparation containing an anti-p53 antisense OLIGOTRIP, or combination of selected anti-p53 antisense OLIGOTRIPs, or one or more pharmaceutically-effective analogs thereof, is administered as specific drug therapy of cancers which carry the p53 gene.
  • the OLIGOTRIP preparation is administered systemically to the individual.
  • autologous bone marrow cells or peripheral blood-derived stem cells
  • a known oncogene or cancer-related gene such as p53, for example
  • specific antisense OLIGOTRIPs to the cancer-related gene in order to eliminate the cancer cells which may be contained in the bone marrow or stem cell transplant specimen.
  • the treated autologous bone marrow cells (or peripheral blood-derived stem cells) are infused back into the patient who has, in the meanwhile, received appropriate surgical, radiation, i muno- and/or chemotherapy.
  • the method for removing contaminating cancerous cells from the marrow cell suspension is straightforward, and comprises the steps of (i) collecting an appropriate amount of bone marrow (preferably about 1500 cc from multiple points in the pelvic iliac crest, although as little as 500 cc and as much as 2000 cc can be used) from the individual who has the cancer, and isolating the nucleated cells from the bone marrow sample; (ii) contacting the nucleated bone marrow cells ex vivo (in culture) with a cytotoxically- effective amount of an antisense OLIGOTRIP which has a base sequence complementary to the duplex DNA of a target gene (such as, for example, the gene encoding p53) present in
  • one method for removing cancerous cells from bone marrow cells obtained from an individual who has cancer involves the steps of: a. collecting bone marrow cells from the having a cancer; b. contacting the bone marrow cells ex vivo with a cytotoxically effective amount of an OLIGOTRIP, or combination of OLIGOTRIPs, which has a base sequence complementary to the duplex DNA of a cancer-related target gene also present in the cells of the cancer; c. thereafter infusing the treated autologous bone marrow cells back into the individual at a clinically appropriate time.
  • the OLIGOTRIP used in treating the bone marrow cells is an anti-p53 OLIGOTRIP.
  • This form of intensive therapy can be further improved by the additional step of administering systemically to the individual, after the bone marrow transplant has engrafted, a therapeutic preparation of this invention containing anti-p53 antisense OLIGOTRIP, administered in an amount sufficient to kill or inhibit the growth of the few p53-positive cancerous cells which may remain in the individual.
  • the anti-p53 antisense OLIGOTRIPs of the present invention can be of significant clinical utility when administered systemically to individuals who have p53-positive cancers, concomitant with or following primary tumor ablation with surgery, radiation and/or chemotherapy. Additional therapeutic gains can be obtained by systematic administration of anti-p53 antisense OLIGOTRIPs to recipients of autologous bone marrow cell suspensions, after the bone marrow, itself purged of contaminating p53-positive cancer cells by treatment with anti-p53 OLIGOTRIPs, has engrafted in the individual.
  • the anti-p53 antisense OLIGOTRIPs are administered in vivo as a systemic therapy, and they can also be administered in vitro , as a procedure for eliminating contaminating p53- positive tumor cells from a suspension of autologous peripheral blood stem cells or autologous bone marrow cells.
  • the physical form of the therapeutic preparation may vary, as discussed more fully hereinafter.
  • Nuclease-resistant backbone structure is the preferred embodiment of the present invention.
  • an "antisense" OLIGOTRIP to be useful as a therapeutic agent following systemic administration, it must survive in solution long enough to reach its designated target gene in the body and block the activity of that target gene. To survive in vivo long enough to be effective therapeutically, the OLIGOTRIP must be resistant to nucleases.
  • OLIGOTRIP The "normal" structure of an OLIGOTRIP is a defined sequence of novel TRIPTIDE bases built upon a sugar-phosphate backbone containing phosphodiester linkages. There is substantial evidence that these phosphodiester linkages are highly susceptible to rapid degradation by a variety of nucleases found in abundance in tissues and cellular fluids. However, attachment of the modified monomeric structures of the present invention to a phosphodiester backbone results in nuclease resistance. OLIGOTRIPs, therefore, do not require a phosphorothioate backbone in order to have nuclease resistance.
  • nuclease-resistant backbone linkage structures can also be employed in the OLIGOTRIPs of this invention.
  • linkage structures are known in the art to be nuclease resistant (for example, see the discussion of nuclease-resistant linkages in Stein et al., Nucleic Acids Research 16.: 3209-3221, 1988).
  • One such linkage is the phosphorothioate linkage.
  • Phosphorothioates are compounds well known in the art, in which one of the non-bridging oxygen atoms in the phosphate portion of a nucleotide is replaced by sulfur.
  • OLIGOTRIP analogs which contain a backbone of phosphorotioate linkages is based on the known resistance of this interbase linkage to degradation by nucleases of many types when used to link the natural nucleotide bases found in DNA or RNA. Since phosphorothioates also have the same number of charges as normal phosphodiester- linked oligomers, they have good aqueous solubility.
  • the conventional nuclease-resistant phosphorothioate backbone linkage does not diminish the potential for sequence specific recognition by the OLIGOTRIP analog for its target gene. Furthermore, it is anticipated that, because of the "abnormal" quinoline and quinazoline bases and the C-glycoside linkage, the OLIGOTRIP would be more stable than DNA.
  • the "antisense" OLIGOTRIPs selected for practice of the present invention may have nuclease-resistant ethyl- or methylphosphonate linkages between the novel TRIPTIDE bases.
  • OLIGOTRIP analogs with these types of linkages may be less efficient at hybridization with a complementary DNA sequence than are the corresponding analogs which incorporate phorphorothioate linkages.
  • OLGIOTRIPs having a methylphosphonate backbone are more lipophilic than are the other analogs, and this may prove advantageous in certain circumstances.
  • nuclease-resistant backbone linkages other than those mentioned above are readily available for incorporation into all or part of a newly-synthesized OLIGOTRIP.
  • nuclease- resisting linkages are continually being developed. It is the intent of the present invention to include within its scope any "antisense" OLIGOTRIP used alone or in combination with other therapies, and which contains such nuclease-resistant backbone linkages. 2. Use of antisense OLIGOTRIPs in pharmaceutical formulations.
  • the therapeutic "antisense" OLIGOTRIPs of the present invention can be formulated into a variety of pharmaceutical compositions, depending upon the protocol to be used for systemic administration.
  • the pharmaceutical compositions employ a therapeutically effective amount of the OLIGOTRIP in a dosage and form sufficient to carry out the purpose of the formulation without causing unacceptable toxicity for the patient, i.e., a "pharmaceutically acceptable and effective amount" of the OLIGOTRIP.
  • the therapeutic amount which represents an optimal therapeutically- effective dose for treatment of a particular clinical problem can be determined empirically by the chemotherapist.
  • OLIGOTRIP OLIGOTRIP compounds of the present invention
  • active ingredients active compounds
  • active compounds any of a number of pharmaceutically-acceptable excipients which facilitate formulation of the active ingredient into suitable dosage form can be used.
  • the preparations are designed for parenteral administration.
  • pharmaceutical compositions designed for oral administration in such forms as tablets, capsules, and dragees, or for rectal administration in the form of suppositories are also considered to fall within the scope of
  • OLIGOTRIP for parenteral administration include aqueous solutions of the active compound prepared in a water- soluble or water-dispersible form.
  • the active compounds are administered as suspensions in appropriate oily injection carriers, i.e., in suitable lipophilic carriers, such as fatty oils (sesame oil being an example) , or synthetic fatty acid esters (ethyl oleate or triglycerides being examples) .
  • suitable lipophilic carriers such as fatty oils (sesame oil being an example) , or synthetic fatty acid esters (ethyl oleate or triglycerides being examples) .
  • Pharmaceutical formulations prepared for aqueous injection may contain substances which increase the viscosity of the suspension such as, for example, sodium carboxymethyl cellulose, sorbitol, and/or dextran.
  • the therapeutic "antisense” OLIGOTRIPs of the present invention may also be administered encapsulated in liposomes.
  • the "antisense” OLIGOTRIPs are contained in corpuscles which consist of concentric aqueous layers interspersed between hydrophobic lipidic layers.
  • the OLIGOTRIPs depending upon their solubility, may be present both in the aqueous layer and in the lipidic layer, or in what is generally termed a liposomic suspension.
  • the hydrophobic layer generally but not exclusively, comprises phospholipids such as lecithin and sphingomyelin, steroids such as cholesterol, more or less ionic surfactants such as a diacetylphosphate, stearylamine, or phosphatidic acid, and/or other materials of a hydrophobic nature which are generally well known in the art.
  • phospholipids such as lecithin and sphingomyelin
  • steroids such as cholesterol
  • more or less ionic surfactants such as a diacetylphosphate, stearylamine, or phosphatidic acid, and/or other materials of a hydrophobic nature which are generally well known in the art.
  • Purging bone marrow suspensions of contaminating tumor cells is presently accomplished either by in vitro incubation of the transplanted marrow cells with potent anti-cancer chemotherapeutic agents, or by contacting the bone marrow cells with immunotherapeutic agents which recognize certain structures unique to the surface membrane of tumor cells.
  • a major difficulty with im unotherapy is that many tumor cells fail to express the tumor-associated membrane structure, and thereby go unrecognized by the immunotherapeutic agent.
  • the immunotherapeutic agent binds to its target but fails to kill the cell.
  • chemotherapeutic agents most of the agents are highly toxic and must be used at relatively high dose in order to maximize tumor cell kill. However, this can lead to death of a large number of normal marrow cells and, in some instances, to graft failure. What is needed, therefore, is a bone marrow purging agent which selectively attacks tumor cells and leaves the normal marrow cells intact.
  • the present invention provides such a novel agent for use with cancers of a variety of types.
  • anti-p53 antisense OLIGOTRIPs are used to remove p53-positive cancer cells obtained from the afflicted individual.
  • bone marrow cells are obtained from an individual who has a p53-positive cancer, using standard procedures, which include aspiration from the pelvic iliac crest of a donor, as described, for example, in U.S. Patents No. 4,481,946 and No. 4,486,188.
  • the patient from whom the bone marrow has been taken is then treated with radiation or chemotherapy to destroy the p53-positive cancer cells which are in one or more organs of the body.
  • the sample of autologous bone marrow cells is then immediately treated with the anti-p53 OLIGOTRIP, as discussed below, and reinfused into the donor as soon as is appropriate.
  • the autologous bone marrow is purged of contaminating p53-positive cancer cells by exposure ex vivo to a cytotoxically-effective amount of an anti-p53 antisense OLIGOTRIP which has a base sequence complementary to that of a p53 target gene present in the cells of the p53-positive cancer.
  • the time of exposure required to obtain complete elimination of the targeted cells in the bone marrow specimen varies depending on tumor cell target, and must be determined empirically. However, exposure times vary from 1 hour to 4 days or longer.
  • the autologous bone marrow purged of all p53 positive malignant cells is transplanted back into the donor.
  • the purged bone marrow cells can be frozen and stored until needed. Procedures for preparing and storing bone marrow samples frozen in a viable state are discussed in detail in U.S. Patents No. 4,107,937 and No. 4,117,881.
  • the circulating peripheral blood contains a substantial number of mononuclear cells which have the potential to regenerate the complete function of the bone marrow compartment of a host organism, such as a human.
  • These peripheral "stem” cells can be isolated, concentrated, and reintroduced via injection into the peripheral circulation as a "stem cell transplant.”
  • Autologous peripheral blood stem cell transplantation has been found important in facilitating recovery of functional bone marrow after high-dose therapy for a variety of malignant diseases.
  • Autologous peripheral blood stem cell transplantation offers certain advantages to autologous bone marrow transplantation, since the general anesthesia used during bone marrow harvesting can be avoided, the collections of peripheral stem cells can be made in an outpatient setting, and the risk of contamination of the transplanted product with malignant cells appears to be less.
  • Methods for purging the peripheral stem cell suspension of contaminating tumor cells are very similar, if not identical, to the procedures outlined above for purging bone marrow cells with anti-p53 antisense OLIGOTRIPs.
  • another embodiment of the present invention is to provide a course of systemically-administered antisense oligotherapy as an adjunct therapy to the individual who received the transplant of autologous bone marrow cells or peripheral stem cells.
  • the tumor cell targets In order for the tumor cell targets to be effectively inhibited by the selected antisense OLIGOTRIPs, the cells must be exposed to the OLIGOTRIPs under conditions that facilitate their uptake by the malignant cells.
  • a preferred procedure for practice of the invention involves placing bone marrow cells into culture, for example, as described by Meagher et al.
  • the concentration of OLIGOTRIP to be used may vary, depending upon a number of factors, including the type of cancerous cells present in the marrow, the type, and specificity of the particular antisense OLIGOTRIP(s) selected, and the relative toxicity of the OLIGOTRIP for malignant and normal bone marrow cells. Although it is expected that, according to the present invention, there is significant inhibition of tumor cell DNA synthesis at OLIGOTRIP concentrations as low as 30 micromolar, optimal inhibition is expected to be observed at concentrations of at least 60 micromolar. With the aid of the techniques set forth in the present disclosure, those of skill in the art should be able to determine the optimal concentration to be used in a given case.
  • the marrow cells After the marrow cells have been exposed to the OLIGOTRIP and, in some cases, cultured as described above, they are then infused into the transplant recipient to restore hemopoiesis.
  • FIGURES 4 and 5 The interstrand nucleotide base pair structures to which the TRIPs specifically associate by hydrogen bonding are shown in FIGURES 4 and 5; the routes for synthesis of the novel TRIP base moieties are shown in FIGURES 10 - 13 and 15. All synthetic intermediates are characterized and confirmed by nuclear magnetic resonance, ultraviolet light absorption, infrared light absorption, and mass spectroscopy.
  • the chromatographic properties of the TRIPSIDEs and the corresponding TRIPTIDEs are determined using reverse phase and ion exchange high-pressure liquid chromatography (HPLC) and capillary electrophoresis. These analytical methods are important in confirming the stability and composition of OLIGOTRIPs (see below) .
  • HPLC reverse phase and ion exchange high-pressure liquid chromatography
  • capillary electrophoresis These analytical methods are important in confirming the stability and composition of OLIGOTRIPs (see below) .
  • Set forth below is a detailed description of the synthesis of four TRIP bases of the present invention: 1) 4-chloro-anti-GC; 2) 5-chloro-anti-CG; 3) 4-chloro-anti-AT; and 4) 5-chloro-anti-TA.
  • the individual steps in the synthetic process are lettered alphabetically, and refer to the letters in the pathway Of FIGURE 10, FIGURE 11, FIGURE 12, and FIGURE 13.
  • Step b The resulting nitro intermediate is reduced by stirring with Rainey nickel catalyst under a hydrogen atmosphere (40 p.s.i.) in acetic acid or ethanol solvent to produce the bicyclic quinoloid compound (COMPOUND II) .
  • This product (which is 2-amino-7- carbomethoxy-4 (IH)-quinoline) is purified by column chromatography and/or crystallization.
  • COMPOUND II contains a methyl protecting group on the substituent at position 7.
  • Other protecting groups can be employed. Such protecting (blocking) groups are well known in the art, and need not be detailed here.
  • Step c The vinylogous amide (l equivalent) is dehydrated to the chloro quinoline (COMPOUND III) by reaction with phosphoryl chloride (0.7 equivalent) in pyridine with heating as required. Purification is enhanced by column chromatography and/or crystallization.
  • Step d The amine (1 equivalent) dissolved in pyridin ⁇ is slowly treated with benzoyl chloride (1.1 equivalent) at room temperature and then with heating to yield the desired amide derivative (COMPOUND IV) , which is 2-benzamido-4-chloro-7-carbomethoxyquinoline.
  • This product is purified by column chromatography and/or crystallization.
  • Step e Another route to 4-chloro-anti-GC is from the methyl 3-nitro-4-chlorobenzoate (COMPOUND V) (1 equivalent) treated with cuprous cyanide (1.1 equivalent in dimethyl sulfoxide (or pyridine) solvent) . Heat as necessary.
  • the product (COMPOUND VI) is purified by column chromatography and/or crystallization.
  • Step f The synthesis then follows essentially the same pathway as detailed above, except the nitrile functionality is hydrolyzed by heating in concentrated sulfuric acid to yield the acid (COMPOUND VII) which is purified by column chromatography and/or crystallization.
  • Step g The acid is then converted into the methyl ester by refluxing in anhydrous methanol in the presence of anhydrous hydrogen chloride.
  • This product (COMPOUND IV) is purified by column chromatography and/or crysta11ization.
  • Steps a, b, g and d are then repeated as described above to yield first (COMPOUND XI) , and then the desired 5-chloro-anti-CG quinoline derivative (COMPOUND XIII) (wherein R' is methyl that is ready for conversion into the TRIPSIDE.
  • These intermediate products are purified by column chromatography and/or crystallization.
  • Step k The nitro group is then reduced with
  • the vinylogous amide is dehydrated as described above (step c) and the product (COMPOUND XVI) is purified by column chromatography and/or crystallization.
  • the resulting quinazoline is benzoylated with benzoyl chloride as described above (step d) .
  • the final product (COMPOUND XVI) is 2-benzamido-4-chloro-7- methoxyquinazoline, and it is purified by column chromatography and/or crystallization.
  • step h Chlorination is carried as described above (step h) and the product (COMPOUND XX) is purified by column chromatography and/or crystallization.
  • 6-chlorobenzaldehyde (1 equivalent) is reduced to the amine by refluxing in benzene or ethanol with iron powder (the powder having been pretreated with concentrated hydrochloric acid) .
  • This amine is then treated with guanidine hydrochloride as described above (step k) to yield the quinazoline (COMPOUND XXIII) which is purified by column chromatography and/or crystallization.
  • brominated TRIPs are prepared according to the synthetic methods summarized in Figure 15. The synthetic steps are indicated by letters, as summarized below:
  • TRIPs 4-bromo-anti-GC, 5-bromo- anti-CG, 4-bromo-anti-AT, 5-bromo-anti-TA.
  • COMPOUNDS XXIV and XXVI represent the quinazoline compounds when Z is a nitrogen, and represent the quinoline compounds when Z is a carbon.
  • COMPOUND XXV and XXVII represent the quinazoline compounds when Z is a nitrogen, and represent the quinoline compounds when Z is a carbon.
  • the resulting 2'-deoxynucleoside derivatives are: 2-amino-4-(2'-deoxy-beta-D-ribofuranos- l-yl) -7-hydroxyquinazoline (which is "anti-AT”); 2-amino- 5-(2'-deoxy-beta-D-ribofuranos-l-yl) -7-hydroxyquinazoline (which is "anti-TA”) ; 2-amino-4-(2'-deoxy-beta-D- ribofuranos-l-yl) -7-carboxyquinoline (which is "anti- GC”); and 2-amino-5-(2'-deoxy-beta-D-ribofuranos—1-yl)- 7-carboxyquinoline (which is "anti-CG”) .
  • the "-yl” term in these chemical descriptions refers to the position of sugar attachment to the TRIP moiety.
  • FIGURES 16 and 17 Alternative methods for synthesizing TRIP deoxyribose synthon ⁇ and TRIPSIDEs of the present invention are set forth schematically in FIGURES 16 and 17, wherein syntheses of anti-AT TRIPSIDE is exemplified. These syntheses were performed according to the methods of Cheng et al. J. Org. Chem. 5_0: 2778-2780, 1985; Farr et al., Carbohydrate Chemistry 9: 653-660, 1990; Zhang & Davies, J. Org. Chem. 57: 4690-4696, 1992; and Farr et al., J. Org. Chem. 5_7: 2093-2100, 1992.
  • the key step is the coupling of the TRIP with the deoxyribose synthon.
  • the procedure is based on the preparation of protected ribofuranoid glycals as described by Cheng et al., 1985, supra , and employs a selective Ireland reductive fragmentation (Li/NH 3 ) of the 2'-3'-isopropylidine group in compound 3_ of Figure 16 (Ireland et al., J. Org. Chem. 43: 786-787, 1978) .
  • the ultimate reagent for the coupling steps (compound 6 of Fig.
  • the 3' ,5'-0-acetyl protecting groups of the 2'-deoxy-TRIPSIDEs are removed by gentle treatment with ammonia in methanol so that the quinoline and quinazoline benzoyl protecting groups are left intact.
  • the unprotected 2'-deoxy-TRIPSIDE in pyridine, containing 0.05 equivalents of dimethylaminopyridine and 1.4 equivalents of triethylamine, is then treated with 1.2 equivalent of 4,4'-dimethoxytrityl chloride (DMTrCL) . More DMTrCL is added until thin layer chromatography shows the reaction to be complete.
  • DMTrCL 4,4'-dimethoxytrityl chloride
  • More DMTrCL is added until thin layer chromatography shows the reaction to be complete.
  • the 5'-DMTr-2'deoxy- TRIPSIDE product is purified by column chromatography and/or crystallization.
  • the structures of the protected TRIPSIDEs anti- TA (COMPOUND XXIII) and anti-AT (COMPOUND XVII) contain aromatic methyl ethers which must be removed and replaced by a more labile protecting group.
  • the methyl group is removed by treatment of the compound with Me 3 SiI in CHCL j (Jung & Lyster, J. Org. Chem. 4_2: 3761, 1977; Minamikawa & Brossi, Tetrahedron Lett., p. 3085, 1978) and esterification of the resulting phenol with PhCOCl.
  • This protecting group is stable to conditions used to hydrolyze the aliphatic sugar acetate groups that are required to functionalize 5'-0 and 3' (or 2')-0 with the 5'-0-dimethoxy-trityl (DMTr) derivative and phosphoramidite reagent, respectively. Removal of the 0- benzoyl group (or any other suitable protecting group which may have been used) is performed during the NH 4 OH cleavage and deprotection of oligomer.
  • DMTr 5'-0-dimethoxy-trityl
  • the phosphorothioate OLIGOTRIPs of the present invention are prepared by reacting the phosphite intermediate with tetraethylthiuram disulfide in lutidine rather than with I 2 . It is also possible to specifically cleave the backbone at a phosphorothioate linkage with iodoethanol (Gish & Eckstein, Science 240: 1520, 1988) via a triester intermediate. The normal phophodiester backbone is relatively stable to this reagent.
  • the OLIGOTRIP with hydrogen phosphate backbone is made using machine compatible H-phosphorate chemistry. It is then converted into the thioate by treatment with S a (Stein et al.. Anal. Biochem. 188: 11, 1990). This method is used to prepare the 35 S-labeled thioate OLIGOTRIP and the normal phosphodiester OLIGOTRIP with a 5'- 35 S-labeled thiophosphate terminus.
  • the solid support derivatized with the desired 3'-end TRIP is prepared by coupling the 3'-O-succinate derivative of the TRIPSIDE to the primary amino groups of commercially available aminomethyl polystyrene resin. This allows for 100-200 ⁇ mol of TRIPSIDE per gram of resin.
  • the actual machine synthesis on an Applied Biosystems, Inc. instrument follows the normal DNA protocols, although coupling conditions and yields are confirmed.
  • the electrophoretic mobility of these oligomers is determined by polyacrylamide gel and capillary electrophoresis.
  • the protecting groups are all labile to the type of NH 4 OH treatment normally used to remove the oligomer from the solid support and to remove protecting groups. Because the TRIPs are C-glycosides, their lability to acid treatment during removal of DMTr protecting groups is low.
  • TRIPSIDEs are relatively stable to acidic conditions, it is critical to determine if isomerization at the anomeric carbon occurs during any of the deprotection steps. To accomplish this, the TRIPSIDEs are relatively stable to acidic conditions, it is critical to determine if isomerization at the anomeric carbon occurs during any of the deprotection steps. To accomplish this, the TRIPSIDEs are relatively stable to acidic conditions, it is critical to determine if isomerization at the anomeric carbon occurs during any of the deprotection steps. To accomplish this, the
  • TRIPSIDEs are treated at pH 2.0 to 12.0 (increments of 1.0 pH unit) and at 20 to 60°C (increments of 5°C) for varying periods of time (up to 48 h) , and then analyzed by HPLC and spectroscopic methods (UV, NMR) to determine their stability to the different conditions.
  • the stability of OLIGOTRIPs toward Serratia marcescens endonuclease, exonuclease III, ung bean nuclease, nuclease P 1 and nuclease S 1 may also be determined by analysis of the OLIGOTRIPs by HPLC, laser desorption/mass spectrometry and polyacrylamide gel electrophoresis. It is believed that the OLIGOTRIPs with the quinoline or quinazoline bases will be generally resistant to enzyme digestion. This is an important issue if the compounds are to be used in biological systems.
  • OLIGOTRIPs ⁇ 6 TRIPs
  • OLIGOTRIPs greater than 6-mers may be analyzed by the time-of-flight instrument, which can provide molecular weight determinations of ⁇ 330,000 Daltons on pmol levels of material.
  • Acridine is coupled to the primary amino group of a hexamethyleneamino linking arm connected to the 5'- end of an OLIGOTRIP via a (CH 2 ) 5 tether using phosphoramidite chemistry previously described (Thuong & Chassignol, Tetrahedron Lett. £9_: 5905, 1988).
  • This intercalator is used because: 1) its attachment to the OLIGOTRIP is straightforward; 2) it shows little preference for A-T or G-C sites; and 3) it has excellent absorption and fluorescence properties that allow it to be used as a marker for intercalation. Intercalation of the acridine nucleus into a DNA base pair stack causes a hypochromic shift. The final product is purified by HPLC. The addition of the intercalator further stabilizes any triple helix interaction and increases the lipophilicity of the OLIGOTRIPs.
  • a modified TRIP is prepared that is appended with a phenanthroline that can chelate copper and generate poorly diffusible reactive oxygen species cable of cleaving DNA (Chen & Sigman, Proc. Natl. Acad. Sci. USA 8_3_: 7147, 1986; Chen & Sigman, J. Amer. Chem. Soc. 110: 6570, 1988).
  • a 5-(6'-bromohexanoamido) -1, 10- phenanthroline Thiong & Chassignol, Tetrahedron Lett.
  • HSP(0 2 )0- is prepared by using bis(2-cyanoethyl) -N,N-diisopropylphosphoramidite at the last step in the machine synthesis and oxidizing the intermediate phosphite with tetraethylthiuram disulfide. This approach can be used to functionalize any OLIGOTRIP and is used to determine the sequence-specific interaction of the OLIGOTRIP with different duplex DNA's (see below) .
  • the attachment of a DNA alkylating functionality, N-methylnitrosourea (MNU) , onto the 5'- terminus of an OLIGOTRIP may be done in two steps.
  • the first step is to incorporate an Fmoc-protected amine (Fig.19 Grant Application) onto the 5'-terminus of an OLIGOTRIP.
  • the oligomer is then removed from the solid support and fully deprotected with base, and the OLIGOTRIP with the 1° amino terminus purified by HPLC.
  • the amino group of the OLIGOTRIP is then condensed with N-hydroxysuccinimidyl N-methyl-N-nitrosocarbamate (Martinez et al., J. Med. Chem.
  • the DNA is purified by HPLC using water (or an aqueous volatile buffer, pH 5.0) with the appropriate organic phase on a C18 column.
  • the quantitative determination of the nitrosourea functionality is achieved by a modification of the Griess calorimetric assay that involves acid-catalyzed denitrosation of a known amount of MNU-OLIGOTRIP and quantitation of the N0 2 (Preussmann et al., In N-Nitrioso Compounds: Analysis and Formation; P. Bogorski, Ed.; LARC, Lyon; p. 81; 1972).
  • alkylating moieties may be attached to OLIGOTRIPs.
  • An OLIGOTRIP with a MNU appendage may be used to determine the sequence specific interaction of an OLIGOTRIP with different duplex DNA's (see below) .
  • poly(anti-TA) n The characterization of poly(anti-TA) n is described in detail below. Analogous procedures may be performed with the other homo- and hetero-OLIGOTRIPs using the appropriate duplex DNA (complementary and non- complementary) targets.
  • the evaluation of the equilibrium binding of OLIGOTRIPs is accomplished by determining the K D for binding of a homo-OLIGOTRIP (e.g. all anti-TA) to selected synthetic DNA duplexes using a gel shift assay.
  • the goal of these relatively straightforward experiments is to determine if oligomers of different lengths bind with K D 's of ⁇ lO "8 M. This is a reasonable benchmark for sequence specific binding. D 's ⁇ 10 "6 are considered to reflect non-specific binding.
  • the binding of the poly(anti-TA) n OLIGOTRIPs may also be monitored by Un ⁇ determined T m denaturation experiments. Traditional triplex structures show increased melting temperatures due to stabilization of the duplex DNA by the third strand (Manzini et al., J. Mol. Biol. 213: 833-843, 1990. Cooney et al., Science 241: 456-459, 1988).
  • poly(anti-TA) n OLIGOTRIPs are designed to demonstrate that the oligotrip is functioning as intended, i.e. poly(anti-TA) n only binds tightly to a target with an embedded poly(dA) :poly(dT) stretch; weak interactions are observed with hetero A-T targets and with G-C targets.
  • the binding of the OLIGOTRIP anti-TA (of various lengths) via a triple-helix motif can be compare with that of the natural pyrimidine triple helix of the same length. Accordingly, poly(anti- TA) n may be compared with poly d(T) n .
  • the binding to duplex target is done in the absence and presence of NaCl(50-200 mM) or MgCl 2 (10-50 mM) .
  • Binding of OLIGOTRIPs to target duplex DNA sequences may also be assessed by the electrophoretic mobility shift assays decribed below. Binding reactions are performed using end-labeled duplex DNA (50,000 cpm, ca. 1 pmol) in 50mM Tris-HCl (pH 7.4) containing 5mM NaCl and lOmM MgCl 2 , tRNA (l ⁇ L of lmg/mL) in a total volume of lO ⁇ L. Reactions are then supplemented with l ⁇ L of an 80% glycerol solution containing bromophenol blue and are loaded on a 20% native polyacrylamide gel prepared in TBE buffer supplemented with 2-4 M MgCl 2 . Electrophoresis is done in this buffer (with recirculation) at 4°C overnight. The resulting gels are imaged and quantitated on a Phospholmager or similar device.
  • OLIGOTRIPs The sequence specificity of (anti-TA) OLIGOTRIP in different targets is tested by DNA footprinting (Jayasena & Johnston, Nucl. Acids Res. 20: 5279-5288, 1992) .
  • Dimethyl sulfate (DMS) methylates DNA at 7-G and the presence of a Hoogsteen base-paired third strand sterically prevents the reaction. Therefore, the degree of protection of a G can be used to determine the stability of a three stranded complex at specific sequences.
  • the OLIGOTRIP anti-(TA) 12 overlaps with half of the Dral recognition site, thereby inhibiting the activity of Dral endonuclease.
  • the same experiment is performed with d(T) 12 and d(A) 12 .
  • One strand is end-labeled in order to provide information on the position of strand cutting.
  • the target sequence can be synthesized and inserted into pBR322 using the .EcoRI (location, 4359) and Hindlll (location, 29) cloning sites.
  • pBR322 has 3 natural Dral sites (locations, 3230, 3249, 3941), it would then be quite easy to determine if the OLIGOTRIP can block endonuclease digestion of only the site that is embedded in an OLIGOTRIP binding domain.
  • the following four examples demonstrate the capacity of the OLIGOTRIPs of the present invention to block the activity of DNA binding proteins at specific sequences, using endonuclease digestions and SV40 DNA polymerization endpoints.
  • One such DNA binding protein is the large T antigen of SV40 virus.
  • the SV40 DNA replication system is used for four reasons:
  • the SV40 virus depends on the host for all replicative functions with the exception of the T antigen, which is a viral gene product.
  • T antigen which is a viral gene product.
  • the viral T antigen is absolutely essential for initiation of SV40 DNA replication (reviewed in Borowiec et al., Cell .60: 181, 1990).
  • the initial step in the pathway of SV40 DNA replication is binding of the large hexameric T antigen structure to DNA sequence controlling elements which comprise the ori , which is the specific region of the SV40 DNA genome that controls the initiation of replication of the entire viral genome.
  • binding site II is absolutely essential for initiating DNA replication. This binding site constitutes the core ori for replication.
  • the core ori for replication is absolutely essential for initiation of SV40 DNA replication.
  • the core ori includes three critical domains: the central domain containing two direct repeats of a "GAGGC" sequence which is the site to which T antigen binds; a 10 base-pair region partially overlapping an imperfect inverted repeat called the early palindrome; and a 17 base-pair region rich in adenines and thy ines called the "AT-tract.”
  • GAGGC central domain containing two direct repeats of a "GAGGC” sequence which is the site to which T antigen binds
  • a 10 base-pair region partially overlapping an imperfect inverted repeat called the early palindrome
  • a 17 base-pair region rich in adenines and thy ines called the "AT-tract."
  • Synthetic oligomers which are complementary to the central GAGGC region and to the early palindrome regions effectively block the DNA binding and the enzymatic (helicase) activities of the T antigen.
  • the sequences of the early palindrome and the central GAGGC region are presented below:
  • the following is exemplary of the capacity of selectively designed OLIGOTRIPs to bind to specific DNA sequences and to block cellular activities dependent on the gene activity of those DNA sequences.
  • DNA binding reactions are performed using the plasmid pJLO (Li & Kelly, 1984, supra) , in which the Hindlll/Sphl fragment of SV40 DNA (nucleotides 5171-5128) is inserted into the pKP45 vector DNA. Plasmid pJLO is propagated and the Hindlll/Sphl restriction fragment is purified. The restriction fragment is labeled with E . coli polymerase I Klenow fragment. OLIGOTRIPs 3'- anti(TA-AT-CG-TA-TA-CG-TA-GC-GC-AT-AT-TA-AT-GC) (corresponding to underlined portion of Sequence I.D. No.
  • T antigen Upon binding to the central region, T antigen unwinds the ori DNA, a process which is ATP-dependent.
  • T antigen The DNA unwinding ability of T antigen is different when it contacts a triple helical template that includes the OLIGOTRIP strand bound to the early palindrome region.
  • T antigen displaces the primer without any specificity for the DNA sequence at that site.
  • the ori specific DNA unwinding assay (Dean et al., Proc. Natl. Acad. Sci. USA 84: 3643, 1987) is utilized, in which the unwinding is reflected by the appearance in electrophoretic gels of faster migrating supercoiled forms of the labeled DNA evident in reactions containing T antigen. This assay is carried out, generally, as follows:
  • DNA synthesis is monitored by agarose gel electrophoresis of product DNA followed by autoradiography. Positive controls for the synthesis reaction include plasmid pJLO- d4, in which a 4 base pair deletion at the origin abolishes T antigen dependent DNA replication.
  • a complementary method to determine efficacy of the OLIGOTRIPs is to determine their ability to block endonuclease digestion at specific restriction sites based on the sequence flanking the endonuclease recognition site.
  • a 5238 base pair parvovirus plasmid, cps-CPV contains two Hindlll cleavage sites (AAGCTT) at position 154 and 815.
  • the flanking sequences at the two sites are GTATGTAAGCTTCCAGGA (Sequence I.D. No. 7) and ACGACGAAGCTTACGCTG (Sequence I.D. No. 8), respectively.
  • the EcoRI linearized plasmid is incubated with OLIGOTRIP 3'-anti(GC-TA-AT-TA-GC-TA-(AT) 2 ⁇ (CG) 2 -AT-(GC) 2 ⁇ AT) (Corresponding to Sequence I.D. No. 7) for various periods of time (5 min, 30 min, 1 hr, 2 hr) prior to adding the restriction enzyme.
  • the number (0, 1 or 2) and position (154 and/or 815) of the sites cut by the Hindlll are determined by electrophoresis on an agarose gel. Cutting occurs only at the 815-position, which is not targeted by the OLIGOTRIP.
  • Parvovirus H-l has two promoter genes, P4 and P6
  • TATA box which is the binding site for the transcription factor "TF-II-D”.
  • An OLIGTRIP that targets the TATA box is tested for its antiviral activity by direct assay of its effects on the transcription of the P4 gene of parvovirus H-l; this is done by primer extension analysis.
  • the P4 TATA box sequence is: 5'-CTGTATATAAGCAG (Sequence I.D. No.
  • the OLIGOTRIP to be used to form a triple helical structure to this target sequence is 3'-anti(GC-TA-AT-TA-AT-TA-AT-AT-GC-CG-AT-GC) (corresponding to underlined portion of Sequence I.D. No. 9) .
  • the transcription factor TF-II-D protects about 20 bp from DNAse-I digestion.
  • the P38 promoter TATA box is targeted and, because P38 is expressed at higher levels than P4, even fewer infected cells are necessary for the assay.
  • the P38 TATA box sequence is: 5'-CTCCTATAAATTCGC (Sequence I.D. No. 11) . This differs from the P4 sequence and it provides a second test of the specificity of the OLIGOTRIP described above. A comparison of the ratios of the P4 to P38 transcripts as affected by dose of OLIGOTRIP is a measure of the specificity of its binding.
  • the P38 promoter has a second target for inhibition, which is an upstream element termed the "TAR" (5'-TTGGTTGGTGAAGAA) (Sequence I.D. No. 12), that is required for the transactivation of the P38 promoter by the NS1 protein.
  • TAR an upstream element termed the "TAR"
  • Nucleotides critical to transactivation have been identified by site-directed mutagenesis. Specific inhibition of this target causes an increase in the ratio of P4 transcripts to P38 transcripts in primer extension assays and in Northern blots when binding to downstream sites is not inhibitory.
  • the P38 promoter is embedded in the transcribed region of the NS1 gene expressed by the P4 promoter.
  • OLIGOTRIP binding to the P38 TATA box which is downstream from the P4 promoter, is used to detect inhibition of transcript elongation in the same experiment as inhibition of transcription initiation.
  • the P38 TATA box is about 1700 nucleotides from the cap site of P4 transcripts. Inhibition of elongation at P38 produces truncated P38 transcripts that are not polyadenylated or correctly spliced. Such transcripts have a short half-life and, thus, are found in reduced abundance.
  • Inhibition of transcription by the OLIGOTRIP is correlated to antiviral effects in an in vitro cell killing assay.
  • Cultured, susceptible target cells are plated in 96-well microtiter dishes and infected at a multiplicity-of-infection of 1 viral particle per 10 cells, to about 1 viral particle per 100 cells.
  • Various concentrations of OLIGOTRIP are added to the wells.
  • the cell viability is measured. This assay is sensitive because the virus has to go through several rounds of infection to amplify the viral titer to a multiplicity of infection sufficient to generate the signal by killing a significant proportion of the cells.
  • a protein designated "rep” binds the terminal hairpin and carries out a site- specific cleavage of the DNA in vitro is done for the parvovirus H-l NSl protein.
  • the substrate is an end- labeled hairpin fragment containing the cleavage site.
  • the products of the cleavage are assayed by denaturing gel electrophoresis. This reaction is inhibited by using an OLIGOTRIP synthesized to specifically bind to the site of cleavage for the 3' hairpin (or for the 5'-hairpin) .
  • the sequence at the 3' cleavage site is 5'-
  • CAGTTCTAAAAAT*GATAAGCG (Sequence I.D. No. 13)
  • "*" indicates the cleavage site and the underlined region is the OLIGOTRIP
  • the sequence at the 5'-hairpin cleavage site is 5'-CTACTGTCT*ATTCAGTTGAC (Sequence I.D. No. 14).
  • OLIGOTRIP 3'-anti(TA-[AT] 5 -TA-GC- AT-TA-AT-AT-GC-CG-GC) (corresponding to underlined portion of Sequence I.D. No. 13) is used in these experiment, and in the in vivo experiment detailed below.
  • the rep protein binds the terminal hairpin in a structure-specific manner and saturates the stem until the cleavage site is bound, inhibition of binding more proximal to the end inhibits the replication as well.
  • alternative sites for OLIGOTRIP binding more proximal to the end are also available for testing. When the normal cleavage site is blocked by OLIGOTRIP, then cleavage at a less preferred site occurs. This is detected in both the in vitro and in vivo assays.
  • the OLIGOTRIP prepared above for in vitro experiments has specificity for the rep cleavage site that is required for DNA replication in vivo .
  • NB cell cultures synchronized by isoleucine starvation, are infected with parvovirus in the presence of a 20 hour block with aphidicolin. Infection proceeds synchronously after reversal of the aphidicolin block. Infected cultures are treated with various doses of OLIGOTRIP and viral DNA extracted and quantitated by Southern blotting at 10 hours post reversal of the block. A 35 mm dish with 1 ml of medium provides enough signal to demonstrate the reduced yield of viral DNA, as confirmed by ethidium bromide staining of gels after electrophoresis.
  • Parvovirus H-l causes a fatal infection of newborn Syrian hamsters or newborn Eppley-strain Wistar rats.
  • the efficacy of OLIGOTRIPs directed against pravovirus targets is exhibited in animals by the protection these OLIGOTRIPs afford to newborn animals which receive a systemic infusion of the OLIGOTRIP prior to receiving an inoculation of the lethal virus.
  • the endpoints used are animal survival times and titers of virus in specific tissues, such as the liver and blood.
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic) ( i ⁇ ) HYPOTHETI CAL : YES
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention porte sur de nouvelles compositions monomères qui sont des structures à base de quinoline ou de quinazoline substituée, capables de former des ponts d'hydrogène spécifiquement avec des paires de base purine-pyrimidine dans une molécule d'ADN bicaténaire Watson-Crick. En outre les nouveaux composés monomères de l'invention peuvent être assemblés en séquences spécifiques pour former des oligomères capables de se lier par la spécificité de la séquence à l'ADN bicaténaire via un motif à triple hélice.
PCT/US1996/004649 1996-04-04 1996-04-04 Composes synthetiques formant une triple helice WO1997037999A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU55339/96A AU5533996A (en) 1996-04-04 1996-04-04 Synthetic triple helix-forming compounds
PCT/US1996/004649 WO1997037999A1 (fr) 1996-04-04 1996-04-04 Composes synthetiques formant une triple helice

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/004649 WO1997037999A1 (fr) 1996-04-04 1996-04-04 Composes synthetiques formant une triple helice

Publications (1)

Publication Number Publication Date
WO1997037999A1 true WO1997037999A1 (fr) 1997-10-16

Family

ID=22254923

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/004649 WO1997037999A1 (fr) 1996-04-04 1996-04-04 Composes synthetiques formant une triple helice

Country Status (2)

Country Link
AU (1) AU5533996A (fr)
WO (1) WO1997037999A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000013681A2 (fr) * 1998-09-04 2000-03-16 Vernalis Research Limited Derives de 4-quinolinemethanol utilises comme antagonistes (i) du recepteur de purine
US6184225B1 (en) 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
WO2002018388A1 (fr) * 2000-08-29 2002-03-07 Takeshi Imanishi Analogues de nucleosides et derives d'oligonucleotides renfermant ces analogues
US6673803B2 (en) 1996-09-25 2004-01-06 Zeneca Limited Quinazoline derivatives and pharmaceutical compositions containing them
US6809097B1 (en) 1996-09-25 2004-10-26 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as VEGF
US9040548B2 (en) 1999-11-05 2015-05-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1451423A (en) * 1974-04-01 1976-10-06 Pfizer 1-oxo-1h-6-substituted pyrimido-1,2-a-quinoline-2-carboxylic acids and derivatives thereof as antiallergy agents
US4031217A (en) * 1975-07-10 1977-06-21 Pfizer Inc. 1-Oxo-1H-6-substituted-pyrimido(1,2-a)-quinoline-2-carboxylic acids and esters useful as antiulcer agents
GB1500666A (en) * 1975-08-01 1978-02-08 Pfizer Substituted pyrimido-quinoline derivatives and pharmaceutical compositions containing them
US4075343A (en) * 1976-09-13 1978-02-21 Pfizer Inc. Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof
US4279912A (en) * 1977-01-20 1981-07-21 Roussel Uclaf Novel imidazoquinolines
EP0398283A1 (fr) * 1989-05-16 1990-11-22 Merrell Dow Pharmaceuticals Inc. Antagonistes d'aminoacides excitatifs

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1451423A (en) * 1974-04-01 1976-10-06 Pfizer 1-oxo-1h-6-substituted pyrimido-1,2-a-quinoline-2-carboxylic acids and derivatives thereof as antiallergy agents
US4031217A (en) * 1975-07-10 1977-06-21 Pfizer Inc. 1-Oxo-1H-6-substituted-pyrimido(1,2-a)-quinoline-2-carboxylic acids and esters useful as antiulcer agents
GB1500666A (en) * 1975-08-01 1978-02-08 Pfizer Substituted pyrimido-quinoline derivatives and pharmaceutical compositions containing them
US4075343A (en) * 1976-09-13 1978-02-21 Pfizer Inc. Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof
US4279912A (en) * 1977-01-20 1981-07-21 Roussel Uclaf Novel imidazoquinolines
EP0398283A1 (fr) * 1989-05-16 1990-11-22 Merrell Dow Pharmaceuticals Inc. Antagonistes d'aminoacides excitatifs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FARMACHVTUTCHNI ZHURNAL, Volume 29, Number 6, issued 1974, R.S. SINYAK et al., "Synthesis of 2,3-Dihydroimiadazo[1,2-C]Quinazoline-2-One s", pages 69-71. *
JOURNAL OF MEDICINAL CHEMISTRY, Volume 31, Number 6, issued 1988, IAN R. AGER et al., "Synthesis and Oral Antiallergic Activity of Carboxylic Acids Derived from Imidazo[2,1-c][1,4]Benzoxazines, Imidazo[1,2-a]Quinolines, Imidazo[1,2-a]Quinoxalines, Imidaza[1,2-a]Quinoxalinones, Pyrrolo[1,2-a]Quinoxalinones, *
KHIMIA GETEROTSIKLITCHESKIKH SOEDINENI, Number 8, issued 1970, BEKHLI et al., "Derivatives of Quinoline-7-Carboxylic Acid. III. 3-Benzyl-4(1H)-Quinoline-7-Carboxylic Acids and Their Derivatives", pages 1115-1118. *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184225B1 (en) 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
US6673803B2 (en) 1996-09-25 2004-01-06 Zeneca Limited Quinazoline derivatives and pharmaceutical compositions containing them
US6809097B1 (en) 1996-09-25 2004-10-26 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as VEGF
US6897210B2 (en) 1996-09-25 2005-05-24 Zeneca Limited Quinazoline derivatives and pharmaceutical compositions containing them
USRE42353E1 (en) 1996-09-25 2011-05-10 Astrazeneca Uk Limited Quinazoline derivatives and pharmaceutical compositions containing them
WO2000013681A2 (fr) * 1998-09-04 2000-03-16 Vernalis Research Limited Derives de 4-quinolinemethanol utilises comme antagonistes (i) du recepteur de purine
WO2000013681A3 (fr) * 1998-09-04 2000-11-23 Vernalis Res Ltd Derives de 4-quinolinemethanol utilises comme antagonistes (i) du recepteur de purine
US6583156B1 (en) 1998-09-04 2003-06-24 Vernalis Research Limited 4-Quinolinemethanol derivatives as purine receptor antagonists (1)
US9040548B2 (en) 1999-11-05 2015-05-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
US10457664B2 (en) 1999-11-05 2019-10-29 Genzyme Corporation Quinazoline derivatives as VEGF inhibitors
WO2002018388A1 (fr) * 2000-08-29 2002-03-07 Takeshi Imanishi Analogues de nucleosides et derives d'oligonucleotides renfermant ces analogues

Also Published As

Publication number Publication date
AU5533996A (en) 1997-10-29

Similar Documents

Publication Publication Date Title
US5683874A (en) Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence
US5426180A (en) Methods of making single-stranded circular oligonucleotides
JP4267233B2 (ja) オリゴヌクレオチドｎ３’→ｐ５’チオホスホルアミデート：それらの合成および使用
US5693773A (en) Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
US5514546A (en) Stem-loop oligonucleotides containing parallel and antiparallel binding domains
JP4383720B2 (ja) オリゴヌクレオチドｎ３’→ｐ５’ホスホルアミデート：合成および化合物；ハイブリダイゼーションおよびヌクレアーゼ耐性特性
US5808036A (en) Stem-loop oligonucleotides containing parallel and antiparallel binding domains
US5674683A (en) Stem-loop and circular oligonucleotides and method of using
JP2003524637A (ja) Ｌｎａ修飾オリゴヌクレオチドの治療上の使用
US5849900A (en) Inhibition of viruses by antisense oligomers capable of binding to polypurine rich tract of single-stranded RNA or RNA-DNA hybrids
JP2005522997A (ja) 交代セグメントを含むオリゴヌクレオチド及びその用途
JP2011172597A (ja) スプライス領域アンチセンス組成物および方法
AU661490B2 (en) Single-stranded circular oligonucleotides
WO1991006626A2 (fr) Formation d'une triple chaine helicoidale en therapie oligonucleotidique
JP2009535383A (ja) 強く結合した塩基で修飾されたオリゴヌクレオチドと人工ヌクレアーゼを組み合わせたアンチセンス作用物質
WO1992010590A1 (fr) Inhibition de transcription par formation de triple helice
WO1994007367A9 (fr) Oligomeres antiviraux liant des voies de polypurine d'arn monocatenaire ou d'hybrides d'arn-adn
US5844110A (en) Synthetic triple helix-forming compound precursors
WO1995026733A1 (fr) Composes de clivage contenant des oligonucleosides et therapies associees
Miller Development of antisense and antigene oligonucleotide analogs
WO1997037999A1 (fr) Composes synthetiques formant une triple helice
US6312953B1 (en) Bifunctional Crosslinking oligonucleotides adapted for linking to a target sequence of duplex DNA
US6645944B2 (en) Inhibition of cellular proliferation by oligonucleotide binding to a chromosomal binding site for p53 protein
JP3904260B2 (ja) ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
US7449571B2 (en) Halogenated aminoquinolines and oligonucleotides containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97536133

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA